VRTX · Vertex Pharmaceuticals Inc / Ma
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Concurrent Repurchase Programs
| Authorized | As of | Remaining | Remaining as of | Source |
|---|---|---|---|---|
| $4,000,000,000 | 2025-05-31 | — | — | 10-Q, filed 2026-08-04 |
| $3,000,000,000 | 2023-02-28 | — | — | 10-Q, filed 2026-08-04 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $806,400,000 | 10-Q, filed 2026-08-04 | ||
| 2025-12-31 | $2,017,400,000 | 10-K, filed 2026-02-13 | ||
| 2024-12-31 | $1,177,100,000 | 10-K, filed 2026-02-13 | ||
| 2023-12-31 | $427,600,000 | 10-K, filed 2026-02-13 | ||
| 2022-12-31 | $0 | 10-K, filed 2025-02-13 | ||
| 2021-12-31 | $1,425,400,000 | 10-K, filed 2024-02-15 | ||
| 2020-12-31 | $539,100,000 | 10-K, filed 2023-02-10 | ||
| 2019-12-31 | $186,000,000 | 10-K, filed 2022-02-09 | ||
| 2018-12-31 | $350,043,000 | 10-K, filed 2021-02-11 | ||